Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Covectra, a Massachusetts-based provider of anti-counterfeiting, diversion control and serialized track & trace technologies and services, has said that its technology systems and unit-dose identification technology are available to support pharmaceutical companies in developing a secure pharmaceutical supply chain, in conformity to the regulatory standards of FDA, reported PMP News.
Subscribe to our email newsletter
In addition to providing technology systems that help all pharmaceutical companies print Standardized Numerical Identification (SNI) codes on all secondary packaging, Covectra offers unit-dose identification technology that provides better security to prescription drugs and medical devices traveling through the complex supply chain to consumers, making each pill or medical device verifiable as an authentic product.
Covectra claimed that its methodology creates a sophisticated, streamlined capability to identify and prevent product diversion and counterfeiting, which, when used in conjunction with its AuthentiTrack software platform, offers a complete portfolio of software and packaging security solutions.
Covectra’s smartphone application can be used to input serialized human readable codes that are unique to a unit package. Once the code is entered into the smartphone, the application checks it against Covectra’s AuthentiTrack software platform which can be used to track the product through all levels of distribution from the point of packaging throughout the supply chain, and ultimately to the consumer. The consumer is then able to verify authenticity, communicate directly with the manufacturer, and enroll in product promotions programs.
Covectra’s security offerings are applied in layers, from simple labels and cartons with proprietary taggants, to sophisticated web-based serialization solutions that provide the brand with ‘end-to-end’ information about the product’s life history and disposition.
Steve Wood, president and CEO of Covectra, said: “With up to 90% of Internet drug sites selling adulterated drugs, diversion control and counterfeiting are concerns that substantially impact the pharma industry.
“With applications providing the opportunity for traceability throughout the supply chain, manufacturers, customs officials and law enforcement can identify counterfeit and diverted product and detect how and where the product entered the supply chain.”